Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00111085 · ClinicalTrials.gov registry record · Phase 2
Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)
A Phase 2 study, sponsored by Idorsia Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 413
- Enrollment target
NCT00111085: Completed Phase 2 study, sponsored by Idorsia Pharmaceuticals.
NCT00111085 is a Phase 2 study that has completed, run by Idorsia Pharmaceuticals. The registered enrollment target is 413 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (211% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00111085, a Phase 2 study, has completed, sponsored by Idorsia Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 413 participants
- Enrollment target
Study Summary
The purpose of the study is to measure how effective and safe three different doses of the drug clazosentan are in preventing vasospasm after subarachnoid hemorrhage.
Primary Outcome
If the patient develops clinical or sonographic changes suggestive of vasospasm prior to or after Day 9 ± 2 and until Day 14 post-aneurysm rupture, an angiogram will be performed to confirm the vasospasm. If vasospasm is documented prior to Day 9 ± 2, the Day 9 ± 2 angiogram is no longer required. In the case that a patient only develops clinical symptoms suggestive of vasospasm later than Day 9 ± 2 and up to Day 14, an additional angiogram should be performed to confirm the diagnosis of vasospa
Interventions
- DRUG Placebo
- DRUG Clazosentan 1 mg/h
- DRUG Clazosentan 5 mg/h
- DRUG Clazosentan 15 mg/h
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 413 participants |
| Start Date | 2005-01-10 |
| Est. Completion | 2006-03-30 |
| Phase | Phase 2 |
What the finished NCT00111085 record still lists
NCT00111085 is an interventional study that assigns participants to a tested intervention. The registered 413 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (211% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00111085 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00111085 about?
NCT00111085 is a clinical study titled "Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH)". The purpose of the study is to measure how effective and safe three different doses of the drug clazosentan are in preventing vasospasm after subarachnoid hemorrhage.
What is the current status of trial NCT00111085?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 413 participants. The study started on 2005-01-10. Estimated completion is 2006-03-30.
What interventions are being tested in trial NCT00111085?
The interventions under investigation include: Placebo (DRUG), Clazosentan 1 mg/h (DRUG), Clazosentan 5 mg/h (DRUG), Clazosentan 15 mg/h (DRUG).
Who is sponsoring clinical trial NCT00111085?
This trial is sponsored by Idorsia Pharmaceuticals, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00111085's enrollment target sits among peer trials
413 93rd of 2000 higher than 1,908 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03592472 · 413 participants · Phase 3
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
- NCT06697197 · 413 participants · Phase 1
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
- NCT04776941 · 414 participants · NA
Expressive Writing for the Management of Stress in Cancer Survivors
- NCT06792552 · 414 participants · Phase 1
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI